We are live on ! Find out more
HALO icon

Halozyme

195 hedge funds and large institutions have $1.72B invested in Halozyme in 2018 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 66 increasing their positions, 58 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

108% more call options, than puts

Call options by funds: $11.5M | Put options by funds: $5.54M

14% more repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 58

1% more funds holding

Funds holding: 193195 (+2)

10% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 31

1.48% less ownership

Funds ownership: 85.29%83.8% (-1.5%)

23% less capital invested

Capital invested by funds: $2.23B → $1.72B (-$516M)

33% less funds holding in top 10

Funds holding in top 10: 32 (-1)

Holders
195
Holders Change
+2
Holders Change %
+1.04%
% of All Funds
4.34%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.04%
New
34
Increased
66
Reduced
58
Closed
31
Calls
$11.5M
Puts
$5.54M
Net Calls
+$6M
Net Calls Change
+$284K
Name Holding Trade Value Shares
Change
Change in
Stake
Fisher Asset Management
26
Fisher Asset Management
Washington
$12.7M +$6.68M +418,581 +94%
ECP
27
Elk Creek Partners
Colorado
$10.8M +$2.22M +139,123 +23%
TA
28
Teachers Advisors
New York
$10.8M +$6.6M +413,847 +128%
Charles Schwab
29
Charles Schwab
California
$10.2M -$3.91M -245,209 -26%
Bank of New York Mellon
30
Bank of New York Mellon
New York
$9.68M -$16.5M -1,032,894 -61%
Federated Hermes
31
Federated Hermes
Pennsylvania
$9.12M +$7.25M +454,383 +269%
TCIM
32
TIAA CREF Investment Management
New York
$7.74M -$154K -9,662 -2%
Macquarie Group
33
Macquarie Group
Australia
$7.32M
Wells Fargo
34
Wells Fargo
California
$6.95M -$598K -37,495 -7%
SEI Investments
35
SEI Investments
Pennsylvania
$6.84M
Two Sigma Advisers
36
Two Sigma Advisers
New York
$6.66M -$4.48M -281,100 -38%
Morgan Stanley
37
Morgan Stanley
New York
$6.61M -$2.28M -143,161 -24%
Axa
38
Axa
France
$6.26M
American Century Companies
39
American Century Companies
Missouri
$6.1M +$3.47M +217,379 +109%
D.E. Shaw & Co
40
D.E. Shaw & Co
New York
$5.89M +$522K +32,721 +9%
AA
41
ALPS Advisors
Colorado
$5.28M +$1.24M +77,631 +27%
Jacobs Levy Equity Management
42
Jacobs Levy Equity Management
New Jersey
$4.79M -$375K -23,500 -7%
Deutsche Bank
43
Deutsche Bank
Germany
$4.75M -$16.6M -1,037,661 -76%
AllianceBernstein
44
AllianceBernstein
Tennessee
$4.62M +$427K +26,786 +9%
IBT
45
International Biotechnology Trust
United Kingdom
$4.58M -$479K -30,000 -7%
Renaissance Technologies
46
Renaissance Technologies
New York
$4.46M -$4.56M -286,000 -48%
BBA
47
Baker Bros. Advisors
New York
$4.39M -$2.39M -150,000 -33%
CS
48
Candriam SCA
Luxembourg
$4.05M +$1.87M +117,000 +73%
Los Angeles Capital Management
49
Los Angeles Capital Management
California
$4.03M +$645K +40,435 +17%
State of New Jersey Common Pension Fund D
50
State of New Jersey Common Pension Fund D
New Jersey
$3.73M

HALO Hedge Fund Activity: Q4 2018 in Review

195 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Halozyme (HALO) for Q4 2018, worth a combined $1.72B — down 23% from $2.23B a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new HALO positions and 31 closed out — a net gain of 3 holders — while 66 added to existing stakes and 58 trimmed.

The largest buyer was JP Morgan Chase, adding an estimated $8.61M. The largest seller was MSD Partners, exiting entirely with an estimated $40.8M sold.

  • 195 institutional investors held Halozyme (HALO) as of Q4 2018, up from 193 in Q3 2018.
  • Funds reported $1.72B of Halozyme stock for Q4 2018, down 23% quarter-over-quarter.
  • 34 funds opened new Halozyme positions in Q4 2018 and 31 closed out, a net change of +3 holders.
  • The largest Halozyme buyer in Q4 2018 was JP Morgan Chase, an estimated $8.61M added.
  • The largest Halozyme seller in Q4 2018 was MSD Partners, an estimated $40.8M sold.

Based on aggregated 13F filings for Q4 2018.